Skip to Main Content

Everyone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown of individuals or companies that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.


Regeneron Pharmaceuticals: The drug maker won regulatory approval of a drug to treat severe eczema, which will carry a $37,000 list price, but probably cost closer to $30,000 after rebates. The company could have priced it still higher, of course, since there is no other drug of this sort currently available. But Regeneron chief executive Len Schleifer had previously signaled he would take this approach in trying to win over payers. His maneuver appears to have worked. Express Scripts, the largest pharmacy benefits manager, called the price fair and indicated it will likely receive preferred placement on its national formulary for insurance coverage. As a result, Regeneron won praise from Wall Street, too.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!